Advisory: Alert wrongly tagged to Lenovo Group Ltd withdrawn
05/12/2023 15:35
An alert on Akeso Inc 9926.HK publishing results from three
investigator-initiated cancer therapy trials on its drug
candidate Cadonilimab at ESMO Asia 2023 has been withdrawn as it
was incorrectly tagged to Lenovo Group Ltd 0992.HK , an
unrelated entity.
There will be no substitute.
STORY_NUMBER:nTUA7LSPNF
STORY_DATE:05/12/2023
STORY_TIME:01:00:26 PM GMT
((Bangalore.newsroom@thomsonreuters.com))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals